News

Industry News

View All » Industry News RSS Feed
 FDA Approves New Opioid, Dsuvia

FDA Approves New Opioid, Dsuvia

The FDA has approved Dsuvia (sufentanil) sublingual tablets for use in medically supervised healthcare settings such as hospitals, surgical centers, and emergency departments for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

Read More »
Endo Pharmaceuticals Recalls Robaxin Due to Incorrect Dosing Label

Endo Pharmaceuticals Recalls Robaxin Due to Incorrect Dosing Label

Endo Pharmaceuticals is voluntarily recalling two lots of Robaxin (methocarbamol tablets) due to incorrect daily dosing information on the label, which misstates the daily dose as “two to four tablets four times a day,” which could result in 16 tablets, rather than the correct dosage of “two tablets three times daily,” which results in 6 tablets.

Read More »
DEA Reschedules Epidiolex, a Marijuana-Derived Drug

DEA Reschedules Epidiolex, a Marijuana-Derived Drug

The Drug Enforcement Agency (DEA) announced that Epidiolex (cannabidiol) oral solution, a drug derived from marijuana, will be rescheduled from a schedule I drug to a schedule V drug.

Read More »
FDA Approves Ajovy for the Preventive Treatment of Migraines

FDA Approves Ajovy for the Preventive Treatment of Migraines

The FDA has approved Ajovy (fremanezumab-vfrm) injections for the preventive treatment of migraines. Ajovy will be available in 225 mg monthly doses, or 675 mg quarterly doses.

Read More »